Randomized, Double-blind, Placebo-controlled Study With Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Latest Information Update: 23 Jun 2026
At a glance
- Drugs Avatrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura; Thrombocytopenia
- Focus Registrational; Therapeutic Use
- Acronyms AVA-PED-301
- Sponsors Dova Pharmaceuticals
Most Recent Events
- 11 Jun 2026 According to a Swedish Orphan Biovitrum media release, data from this study will be presented at the 2026 Congress of the European Hematology Association (EHA2026), taking place June 11-14 in Stockholm, Sweden.
- 15 Jan 2026 Status changed from active, no longer recruiting to completed.
- 01 Oct 2025 Planned primary completion date changed from 14 Aug 2023 to 28 Oct 2025.